Skip to content

The power of IRBM is our ability to build a full research program based on your ideas and guide them through to IND submission; and more than a third of our client partnerships involve integrated projects. This integrated approach combines biology, chemistry, ADME and in vivo studies, for small molecule, peptide or antibody discovery. Each and every project benefits from our collaborative teams of scientists and technical experts working together across disciplines in a single state-of-the-art facility near Rome. High-quality science and our collaborative, efficient and agile approach, ensures integrated program success.

4 KEY MARKETED THERAPIES THAT IRBM HAS CONTRIBUTED TO
YOUR PROJECT IS IN SAFE HANDS

With 4 drugs on the market and more than 25 candidates delivered, our scientific team understands that each integrated drug discovery project is unique. We overcome challenges by defining project goals and candidate requirements together with our clients and delivering customized, multidisciplinary solutions. Many studies are exploratory and where necessary, we’ll use our strong scientific foundation to develop novel and bespoke methods and experimental set-ups. For every project, we leverage our team’s problem-solving capabilities and scientific know-how to deliver superior drug candidates, quickly and cost effectively.

THE BENEFITS OF WORKING WITH IRBM:
  • Broad, industrial experience and strong scientific foundation in translational research with different therapeutic modalities and targets
  • Drug discovery expertise and know-how with a proven track record, spanning from target validation, hit identification, hit to lead, lead optimisation and candidate selection
  • Reduced cycle times and faster program progression due to seamless transitions between highly integrated disciplines
  • A single point of contact for program management, reducing complexity and extraneous resource demand
  • Innovative scientific advice and insights from a team of passionate experts
  • A flexible approach to drug discovery to increase the chances of your project’s success and achieve a higher-quality drug candidate with well-optimized properties
  • Strong support for IP analyses and protection
  • Unique, proprietary libraries (small molecules and phage display of peptides and monoclonal antibodies)

Whatever your needs, our team can support your research, accelerate your integrated drug discovery program and deliver high-quality candidates to enter the clinic, leaving you free to focus on what comes next.

Contact us for more info   Get in touch

A SELECTION OF PROJECTS WE HAVE DELIVERED TO OUR PARTNERS
Modality Therapeutic area Mechanism of Action Deliverable Company – Location
Peptide Inflammation PPI inhibitor Lead Opt. (multiple) Big Pharma – US, EU
Peptide Metabolism PPI inhibitor Pre-clinical candidate Big Pharma -US
Peptide Oncology Receptor Targeting Hit series (multiple) & Lead Opt. (multiple) Big Pharma. Mid-Size Pharma, Biotech – US, JP
Peptide Infectious Disease PPI inhibitor Lead Opt. Big Pharma – US
Peptide Cardiovascular Receptor Agonist Pre-clinical candidate Big Pharma, Biotech -EU
Small Molecule Neurodegeneration PPI Lead ID Non-Profit – US
Small Molecule Oncology PPI Lead Opt. Biotech – EU
Small Molecule Infectious disease PPI Pre-clinical candidate (out-licensed) Government/Grants -EU
Small Molecule Infectious disease Allosteric Inhibitor Lead Opt. Government/Grants – EU
Small Molecule Oncology Allosteric Inhibitor Pre-clinical candidate Government/Grants – EU
Monoclonal Antibody Oncology Immune checkpoint agonist Lead Opt. Cancer Hospital – US
Monoclonal Antibody Oncology Receptor Targeting Pre-clinical candidate Government/Grant – US
Back To Top